Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Metadoxine→

Metadoxine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
74536-44-0
Molecular formula
C13H18N2O6
Molecular weight
298.29 g/mol
Drug class
Pyridoxine-pyrrolidone carboxylatealcohol-metabolism modulator
Mechanism of action
A salt of pyridoxine and pyrrolidone carboxylate that has been studied for effects on ethanol metabolism and clearance, hepatic redox state and glutathione-related pathways. Its complete clinical mechanism remains uncertain.
Indications / reported uses
  • Used in some countries as an adjunct in acute alcohol intoxication and alcohol-related liver disorders; current evidence and authorised indications vary by jurisdiction. It is not a substitute for supportive care in alcohol poisoning.

Sources: https://pubmed.ncbi.nlm.nih.gov/11923586/ · https://pubmed.ncbi.nlm.nih.gov/42632932/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Metadoxine Environmental Risk Assessment (ERA) (the Metadoxine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.